Merus re­ceives FDA ac­cel­er­at­ed ap­proval to treat NRG1+ can­cers

The Dutch biotech Merus re­ceived the first-ever FDA ac­cel­er­at­ed ap­proval for a sys­temic treat­ment tar­get­ing a spe­cif­ic ge­net­ic fu­sion in pa­tients with ei­ther non-small cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER